An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy. The VECTRA Study

2024-519964-42-00 Protocol STP938-301 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 2 Jul 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 7 sites · Protocol STP938-301

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 23
Countries 1
Sites 7

Thrombocythaemia

Key facts

Sponsor
Step Pharma
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
2 Jul 2025 → ongoing
Decision date (initial)
2025-05-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-519964-42-00
ClinicalTrials.gov
NCT06786234

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Thrombocythaemia

VersionLevelCodeTermSystem organ class
21.0 PT 10015493 Essential thrombocythaemia 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Step Pharma

Sponsor organisation
Step Pharma
Address
101 Rue De Sevres
City
Paris Cedex 06
Postcode
75272
Country
France

Scientific contact point

Organisation
Step Pharma
Contact name
VP, Head of Clinical Operations

Public contact point

Organisation
Step Pharma
Contact name
VP, Head of Clinical Operations

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 13 7
Rest of world
United Kingdom
10

Investigational sites

France

7 sites · Ongoing, recruiting
Institut Paoli Calmettes
Service d‘Onco-Hématologie, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Institut de Cancérologie du Gard
Hématologie Clinique, Rue du Pr Henri Pujol, 30000, NIMES
Hopital Saint Louis
Centre d’investigation Clinique, 1 Avenue Claude Vellefaux, 75010, Paris
Centre Hospitalier Universitaire De Nantes
Hématologie Clinique, 1 Place Alexis Ricordeau, 44000, Nantes
Hôpital Cavale Blanche CHU de Brest
Institut de Cancérologie et d’Imagerie, Bd Tanguy Prigent, 29069, Brest
Institut Gustave Roussy
Hématologie Clinique, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Hospitalier Universitaire De Nice
Hematology, 151 Route De Saint Antoine, 06200, Nice

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-07-02 2025-07-09

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-06 France Acceptable
2025-05-06
2025-05-13
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-03 France Acceptable
2025-05-06
2025-06-03
3 SUBSTANTIAL MODIFICATION SM-1 2025-06-03 France Acceptable
2025-06-30
2025-07-17
4 SUBSTANTIAL MODIFICATION SM-2 2025-09-29 France Acceptable
2025-10-14
2025-10-22
5 NON SUBSTANTIAL MODIFICATION NSM-2 2025-10-24 France Acceptable
2025-10-14
2025-10-24
6 NON SUBSTANTIAL MODIFICATION NSM-3 2025-11-07 France Acceptable
2025-10-14
2025-11-07
7 SUBSTANTIAL MODIFICATION SM-3 2025-12-19 France Acceptable
2026-02-20
2026-02-20